Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis.
Louis ManièreJohan NobleFlorian TerrecHamza Naciri BennaniEloi ChevallierBénédicte JanbonRaphaele GermiMathilde BugnazetFarida ImerzoukenePaolo MalvezziLionel RostaingThomas JouvePublished in: International urology and nephrology (2020)
Everolimus plus low-dose TAC given to de novo KTRs was associated with low rates of CMV disease, especially in R+ patients with no CMV prophylaxis.
Keyphrases